跳至主要内容
临床试验/NCT06415799
NCT06415799已完成不适用

Verification of Investigational Pulse Oximetry Devices With the Abbreviated Sensor Line in Adult Volunteers

Medtronic - MITG2 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2024年2月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
28
试验地点
2
主要终点
Verification of Saturation Accuracy

研究概览

简要总结

The verification of an investigational pulse oximetry board to verify pulse rate and saturation accuracy over a specified saturation range in diverse populations.

详细描述

To verify the SpO2 and pulse rate accuracy in comparison to reference-standard blood measurements. To achieve paired observations of SpO2 and SaO2 values over the specified SpO2 accuracy range of the prototype pulse oximeter on a group of healthy adult volunteers. The fraction of inspired oxygen (FiO2) delivered to test subjects is varied to achieve a series of targeted steady-state saturation periods. In this study, the investigational pulse oximetry PCBA system saturation measurements will be compared to saturation measurements made by a multi-wavelength CO-oximeter, taken from arterial blood samples from a diverse pool of healthy human subjects.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female subjects 18 to 50 years of age
  • Subject is willing and able to comply with study procedures and duration
  • Subject is willing to sign an informed consent
  • Subject weighs >40kg
  • Subject is a non-smoker or has not smoked within 2 days prior to the study
  • Cleared same day health assessment form and health screening
  • Successful perfusion index ulnar/ulnar+radial ratio test showing adequate collateral blood flow.

排除标准

  • Subject is considered as being morbidly obese (defined as BMI >39.5)
  • Compromised circulation, injury, or physical malformation of fingers, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the sites utilized)
  • Females of childbearing potential who are pregnant, who are trying to get pregnant, or who have a urine test positive for pregnancy on the day of the study
  • Subjects with COHb levels >3% as assessed by CO-Oximetry during the procedure
  • tHb < 10 g/dl as assessed by CO-Oximetry during the procedure
  • MetHb ≥ 2% as assessed by CO-Oximetry during the procedure
  • Subjects with known respiratory conditions such as:
  • uncontrolled / severe asthma
  • flu or influenza type infection
  • pneumonia / bronchitis
  • shortness of breath / respiratory distress
  • unresolved respiratory or lung surgery
  • emphysema, COPD, lung disease
  • recent COVID (last 2 months)
  • Subjects with known heart or cardiovascular conditions such as:
  • hypertension: systolic >140mmHg, or Diastolic >90mmHg on 3 consecutive readings
  • have had cardiovascular surgery
  • chest pain (angina)
  • heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen)
  • previous heart attack
  • blocked artery
  • unexplained shortness of breath
  • congestive heart failure (CHF)
  • history of stroke
  • transient ischemic attack
  • carotid artery disease
  • myocardial ischemia
  • myocardial infarction
  • cardiomyopathy
  • implantable active medical device such as pacemaker or automatic defibrillator
  • Self-reported health conditions as identified in the Health Assessment Form
  • uncontrolled thyroid disease
  • kidney disease / chronic renal impairment
  • history of seizures (except childhood febrile seizures)
  • history of unexplained syncope
  • recent history of frequent migraine headaches
  • recent symptomatic head injury, within the last 2 months
  • cancer requiring chemotherapy, radiation, or current treatment
  • subjects with known clotting disorders
  • history of bleeding disorders or personal history of prolonged bleeding from injury
  • history of blood clots
  • sickle cell trait or disease
  • current use of blood thinner: prescription or daily use of aspirin
  • subjects with Severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors
  • participants with severe allergy to iodine (only applicable if iodine is used)
  • subjects with prior or known severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocain) or heparin
  • arterial cannulation within the last 30 days prior to study date, (this may exclude only one radial artery site, left or right)
  • history of clinically significant complications from previous arterial cannulation
  • unwillingness or inability to remove colored nail polish or colored artificial nails other than clear from test digits
  • other known health condition, upon disclosure in Health Assessment form

研究组 & 干预措施

Healthy Volunteers

Observational Study

结局指标

主要结局

Verification of Saturation Accuracy

时间窗: 2.5 hours

Saturation accuracy in a diverse subject population over a specified saturation range. The acceptance criteria for the investigational Pulse Oximetry PCBA system, SpO2 across the saturation range of 70-100%: SpO2 Max-A ±2% (ARMS) OxySoft-N ±2% (ARMS) Max-Fast ±2% (ARMS) FlexMax ±2.5%(ARMS) DS-100A ±3% (ARMS) D-YS ±3% (ARMS)

Verification of Pulse Rate

时间窗: 2.5 hours

Pulse rate in a diverse subject population over a specified saturation range. The acceptance criteria for pulse rate from 20-250 BPM over a specified saturation range of 70-100%: Pulse Rate Max-A ≤3% BPM (ARMS) OxySoft-N ≤3% BPM (ARMS) Max-Fast ≤3% BPM (ARMS) FlexMax ≤3% BPM (ARMS) DS-100A ≤3% BPM (ARMS) D-YS ≤3% BPM (ARMS)

Proposed claim verification for pulse rate and saturation accuracy

时间窗: 2.5 hours

Acceptance criteria for * SpO2 across the saturation range of 70-100% * Pulse rate from 20-250 BPM

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

OM2 Abbreviated Sensor Verification | 临床试验